Subject Index

A

Abdominal fat. *See* Visceral fat
Aborigines, Australian
  cardiovascular risk in, 472, 1269
  glucose intolerance in, 1269
Abortion, spontaneous, pre-conception care and, 514
Acanthosis nigricans, insulin resistance and, 885
Acarbose
  as adjuvant to sulfonylurea therapy, 252
  glucose intolerance and, 1190
  ileus and, 1033
  indications for, 94
ACE. *See* Angiotensin-converting enzyme (ACE)
Adherence to diabetes care, patient participation and, 1153
Adipocyte, 1040
  dedifferentiation of, TNF-α and, 1283
Adipose tissue
  metformin and, 160
  subcutaneous distribution of, visceral fat and, 1404
Adolescent
  Eikenella corrodens infection in, 1011
  microalbuminuria in, 369
β_3-adrenergic receptor, genetic variations in, 271, 1034
Adult-onset IDDM, immunogenetic markers in, 241
African-Americans
  amputation incidence and proportion in, 48
  in behavioral weight control program, 409
  black South Africans vs., NIDDM in, 1451
  lipoprotein(a) levels in, 1129
  metabolic syndrome in, 414
  mortality of, 1344
Aging. *See also* Elderly patients
  cardiovascular risk and, 587
  diabetes incidence and, 114, 1279
  hypoglycemia and, 544
  pancreatic β-cell function in, 8
Albuminuria. *See also* Macroalbuminuria; Microalbuminuria
  ACE gene polymorphism in, 1420
  5-year prospective study of, 171
  incidence of, 486
  as predictor of diabetic complications, 1243
  serum sialic acid and, 130
Alcohol intake, NIDDM and, 509
Aldehyde dehydrogenase, mitochondrial, genetic mutation in, 1423
Allergic reaction, to latex, 184, 546
α-cell function, mitochondrial gene abnormalities and, 1166
Altitude, blood glucose meter and, 1430
Amino acid turnover, in gestational diabetes, 591
Amputation
  of foot, in Pima Indians, 704
  of great toe, foot deformities and ulcers after, 165
  incidence of, 1006
    in minority subjects, 48
  of lower extremity
    incidence of, 1006
    in Nauruans, 710
    risk factors for, 95, 607
Amylin
  islet, glipizide and, 883
  pathophysiological effects of, 551
Amyloidosis, islet, in congenital generalized lipodystrophy, 28
Androgen, glucose intolerance and, in postmenopausal women, 1399
Angiopathy, HbA_{1c} threshold for, 183
Angioplasty, percutaneous transluminal, for foot ulcer, 1261
Angiotensin-converting enzyme (ACE), genetic polymorphism of, albuminuria and, 1420
Angiotensin-converting enzyme (ACE) inhibitor
  genetic mutation of, 543
  ketonuria and, 673
  renal and cardiovascular effects of, 1225
  reversible hyperkalemia and, 781
1,5-Anhydroglucitol, in nondiabetic serum, 940
Antimicrobials, for foot infection, 638
Antiphospholipid syndrome, retinal artery occlusion in, 92
Antroduodenal motility, in IDDM, 21
Aortic distensibility, familial NIDDM and, 501
Apolipoprotein(a), nephropathy and, 1036, 1382
Arginine, vascular responses to, metformin and, 934
Arterial calcification, in Pima Indians, 968
Asian subjects, nondiabetic, hyperinsulinemia in, 39
Atherosclerosis
  in African-Americans, 414
  insulin resistance and, 274
  visceral fat accumulation and, 287, 292
Auditory evoked potentials, in IDDM, 1220
Australian Aborigines
  cardiovascular risk in, 472, 1269
  glucose intolerance in, 1269
Autonomic neuropathy, 751
  cardiac, hyperglycemia and, 880
  disease duration and, 960
  gastric emptying delay in, NMR imaging of, 1075
  pancreatic polypeptide response to, 778
  subcutaneous insulin infusion for, 90

B

BABY-DIAB Study, 1456
Balloon angioplasty, for foot ulcer, 1261
Behavioral change strategies, in DCCT, 648
Behavioral weight control program, effectiveness of, 409
β-cell. *See also* Islet cell
  aging and, 8
  GAD antibody and, in children with IDDM, 74
  mitochondrial gene abnormalities and, 1166
Birth date, time-space clustering at, in children with IDDM, 328
Black South Africans, NIDDM in, vs. African-Americans, 1451
Blindness. *See* Visual loss
Blood cell, red, Na-Li countertransport activity in, in non-nephropathic diabetic twins, 32
Blood flow, peripheral, metformin and, 160
Blood glucose
  monitoring of. *See* Glucose meter; Monitoring of blood glucose
  in obesity, exercise intensity and, 341
  in postmenopausal women, 333
Body fat
  central, measurement of, 1033
  distribution of, insulin resistance and, 287, 292, 920
Bone mineral density, hyperinsulinemia and, 1388
Bovine serum albumin, antibodies to, in children with IDDM, 126, 1308
Bovine serum albumin peptide, in infant formula, 1364
Brain function
  in ketoacidosis, 1455
  in NIDDM, 361
Brainstem auditory evoked potentials, in IDDM, 1220
Brazilians with IDDM, anti–bovine serum albumin antibodies in, 126
Bromocriptine (Ergoset), for weight loss, 667

C

Calcification, arterial, in Pima Indians, 968
Calcium
  hyperglycemia and cardiac mass and, 1393
  platelet, in end-stage renal failure, 1062
Cancer. *See site of tumor, e.g.*, Pancreatic carcinoma
Capillary HbA_{1c}
  collection of, at home, 1307
  on filter paper, 142
Captopril
  circulating catecholamines and, 236
  ketonuria and, 673
  for nephropathy, economics of, 1051
Carbohydrate
  gastric emptying of, 468
  ingestion of
    energy balance and, 1142
    α-glucosidase inhibitor effects after, 642
    hypoglycemia drugs and, 498
  supplementary, exercise and, 575
Cardiac innervation
  coronary artery disease symptoms and, 231
  disease duration and, 960
  hyperglycemia and, in normal subjects, 880
Cardiac ischemia, death from, sex hormones and DHEA-SO_4 in, 1045
Cardiac mass, calcium and, 1393
Cardiovascular disease, 187, 1459. *See also* Atherosclerosis
Cardiovascular risk
  ACE inhibitors and vitamin E and, 1225
  in Australian Aborigines, 472, 1269
  cigarette smoking as factor, 112
  in elderly patients, 587
  in Europe, 689
  hyperglycemia as factor, 450
  islet cell antibodies and, 60
  metformin and, 64
  in NIDDM, 1265
  retinopathy and, 1445
  socioeconomic status and, 419, 423
  syndrome X and, 275
  urinary albumin excretion and, 1243
Caretaker, of children with IDDM, insulin dose measurement by, 56
Catecholamines, in plasma, captopril and, 236
Caucasians
  in behavioral weight control program, 409
  mortality of, 1344
  non-Hispanic, amputation incidence and proportion in, 48
$CD8^+$ T-cell activation, in prediabetic twins, 1177
Cereal, high β-glucan, NIDDM subjects and, 831
Cerebral infarction, hypoglycemia and, 1001
Cesarean section, infection after, 597
Children. *See also* Children with IDDM; Children with NIDDM
  of diabetic parent(s), 822, 827
    islet cell antibodies in, vaccines and, 1456

pubertal, thyroxine-binding globulin in, 246
Children with IDDM
anti–bovine serum albumin antibodies in, 126, 1308, 1364
dietary intake of, 1370
GAD antibodies in, 901
β-cell function and, 74
hospital admissions for, 431
incidence of, in Rome and Lazio region, 70
insulin dosage measurement for, caretaker measurement of, 56
islet cell antibodies in, 1452
metabolic control in, 318
pancreatic size in, 777
parental diabetes and, 827, 1456
psychiatric disorders in, 318
self-care autonomy in, 119
seric IgA production in, 779
subcutaneous vs. intramuscular insulin injection in, 1434
time-space clustering of date at birth in, 328
zinc deficiency and, 373
Children with NIDDM
maternal diabetes and, 822
parental diabetes and, 827
Chinese, metabolic syndrome in, 953
Cholestasis, glibenclamide-induced, 385
Cholesteryl ester transfer, pancreas-kidney transplantation in, 1108
Chromosome 1 2q, MODY3 locus on, diabetic complications and, 915
Cigarette smoking. *See* Smoking
Clamp technique, advantages of, 278
Classification of diabetes, 270, 676
Cognitive function, glycemic control and, 656
Cold pressor test, pain during, 722
Colombian Amerindians, lack of diabetes in, 900
Community setting, rapid HbA_{1c} testing in, 764
Complement C4, polymorphism of, IDDM susceptibility and, 53
Complications. *See also* Diabetes Control and Complications Trial (DCCT); EURODIAB IDDM Complications Study; *specific complication*
avoidance of, 927
MODY3 locus on chromosome 1 2q and, 915
studies of, GHb measurement differences in, 726
Conception, medical care before. *See* Preconception care
Congenital generalized lipodystrophy, islet amyloidosis in, 28
Congenital malformations, pre-conception care and, 514
Coronary artery bypass surgery, mortality and morbidity after, 698
Coronary artery disease
insulin resistance in, 1
painful vs. asymptomatic, cardiac innervation and, 231
retinopathy as predictor of, 1445
Cortical blindness, hypoglycemia and, 272, 1001
Cost benefit, of preconception care, 384
Cost of diabetes, 1416
Cow's milk protein, bovine serum albumin peptide in, in infant formula, 1364
Cremona study, 1279

D

DCCT. *See* Diabetes Control and Complications Trial (DCCT)
Death
after coronary artery bypass surgery, 698
diabetes center attendance and, 211
hypertension and, 305
from ischemic heart disease, sex hormones and DHEA-SO_4 in, 1045
in Pima Indians, 107
from nephropathy, 777, 779
proteinuria and, 305
racial differences in, 1344
sudden, long QT interval and, 1010
Denmark, IDDM epidemiology, 801
Depression, NIDDM onset and, 1097
Dermagraft, for foot ulcers, 350
DHEA-SO_4, sex hormones and, and death from ischemic heart disease, 1045
Diabetes center, survival probability and, 211
Diabetes Control and Complications Trial (DCCT)
behavioral change strategies in, 648
patient reactions to, 873
quality-of-life outcomes in, intensive therapy and, 195
retinopathy in, 1375
Diabetes mellitus
incidence and prevalence of, in Manitoba, 807
lack of, in Colombian Amerindians, 900
Diabetes Prevention Trial, 96
Diet
after pancreas transplantation, 735
carbohydrates in. *See* Carbohydrate, ingestion of
of children with IDDM, 1370
high fat and high carbohydrate, energy balance and, 1142
linseed and fish oil in, NIDDM control and, 463
miglitol and, 559
self-management of, office-based intervention in, 835
sucrose and fructose in, metabolic effects of, 1249
in tropical countries, 1014
of Wanigela people of Papua New Guinea, 457
Dipyridamole thallium myocardial scintigraphy, of vascular surgery patient, 355
DQB1 typing, neonatal diabetes and, 1308
Drug use, in diabetic patients, 992
Dyslipoproteinemia, in NIDDM, GLP-1 for, 1200

E

Egyptian deserts, diabetes prevalence in, 92
Eikenella corrodens infection, 1011
Elderly patients. *See also* Aging
cardiovascular risk in, 587
glucose level and pulmonary function in, 1441
NIDDM in, 1320, 1326
Endothelial cells, monocyte binding to, hypertriglyceridemia and, 1122
Endothelial growth factor, vascular, in aqueous humor, rubeotic glaucoma and, 1306
Endothelin-1, insulin and, 504
Energy balance, high-fat/high-carbohydrate diet and, 1142
Enteral feeding, guar gum in, 899
Epidemiology of Diabetes Complications Study, renal disease in, 219
Erectile dysfunction, prevalence of, 133
Ergoset (bromocriptine), for weight loss, 667
Erythrocyte, Na-Li countertransport activity in, in non-nephropathic diabetic twins, 32
Ethnicity. *See specific ethnic group*
ETS (exercise thallium 201 scintigraphy), false-positive, 185
EURODIAB IDDM Complications Study
renal disease in, 219
socioeconomic status and diabetic complications in, 423
Europe, cardiovascular risk in, 689
Exercise
carbohydrate supplementation and, 575
intensity of, in obesity, 341
oxidative stress and, 569
peripheral vascular resistance and, in young IDDM patients, 1286
Exercise thallium 201 scintigraphy (ETS), false-positive, 185

F

Familial diabetes. *See also* Children, of diabetic parent(s)
and 1,5-anhydroglucitol in nondiabetic serum, 940
aortic distensibility and, 501
incidence of, 5827
mitochondrial DNA mutations in, 507
Fat. *See also* Body fat; Obesity
abdominal. *See* Visceral fat
dietary, energy balance and, 1142
Fat replacers, in nutrition therapy, 1294, 1302
Fatty acids
insulin resistance and, 394
n-3 type of, NIDDM control and, 463
Fibrinogen, in plasma, 157
β-fibrinogen gene, as cardiovascular risk factor, 1265
Fibrocalculous pancreatic diabetes, 1274
Filter paper, capillary HbA_{1c} on, 142
Finland, IDDM risk in, HLA-DQB1 genotype and, 795
Fish oil
insulin resistance and, 1207
nephropathy and, 1214
NIDDM control and, 463
Food, pancreatic polypeptide response to, 778
Foot
amputation of, in Pima Indians, 704
deformities of, after great toe amputation, 165
dynamic pressure on, reduction of, 818
infections of, antimicrobials for, 638
osteomyelitis in, conservative surgery for, 1257
ulceration of
after great toe amputation, 165
Dermagraft for, 350
hyperbaric oxygen therapy in, 1338
PTA for, 1261
reducing dynamic foot pressure in, 818
Formula, for infant feeding, bovine serum albumin peptide in, 1364
Fructose, dietary, metabolic effects of, 1249

G

GAD antibodies
β-cell function and, in children with IDDM, 74
in children with IDDM, 901
disappearance of, in progressive IDDM, 1031
in Thailand, 674
Gastric emptying

delayed, autonomic neuropathy with, NMR imaging of, 1075
in NIDDM, 468
postprandial walking and, 1306
Genetic mutation
of glucagon receptor, 546
mitochondrial, α- and β-cell dysfunction and, 1166
Genetics
of adult-onset IDDM, 241
of familial NIDDM, 507
of insulin resistance, 396
of NIDDM, 864
GENNID study, 864, 892
Gestational diabetes mellitus. *See also* Pregnancy
diagnosis of, 12
glucose and amino acid turnover in, 591
increased proinsulin-to-insulin ratio after, predictive value of, 17
lipid levels in, 1351
NIDDM vs. IDDM after, 653
recurrent, 1348
screening for, 12
GHb. *See* Glycated hemoglobin (GHb)
Glaucoma, rubeotic, aqueous humor VEGF and, 1306
Glibenclamide
GLP-I and, 857
liver toxicity of, 385
Glimepiride
once-daily, 1194
response to, after sulfonylurea therapy, 849
Glipizide, islet cell hormones and, 883
Glomerular filtration rate, 5-year prospective study of, 171
GLP-I. *See* Glucagon-like peptide I
Glucagon, islet, glipizide and, 883
Glucagon-like peptide I
glibenclamide and, 857
in IDDM, 580
for NIDDM dyslipoproteinemia, 1200
in tablet, 843
Glucagon receptor, genetic mutation of, in Japanese patient, 546
β-glucan, cereals high in, NIDDM subjects and, 831
Glucose intolerance
acarbose and, 1190
androgen activity and, in postmenopausal women, 1399
in Australian Aborigines, 1269
cigarette smoking and, 112
lipid metabolism in, 365
methane-producing status and, 549
in northern Sudan, 1126
prevalence of, 663
pulmonary function and, in elderly patients, 1441
Glucose measurement
in blood. *See* Blood glucose
in urine. *See* Urine glucose, measurement of
Glucose metabolism
metformin effect on, 1185
in obesity, exercise intensity and, 341
Glucose meter
accuracy of, 903, 1412
altitude and, 1430
in pregnancy, 1031
temperature and, 771
Glucose tolerance tests
glucose effectiveness in, 1018
oral, 271
α-Glucosidase inhibitor, after carbohydrate ingestion, 642
Glycated hemoglobin (GHb)
assays for, interlaboratory variations in, 730
cardiovascular risk and, 450
complications risk and, 726
in pregnancy, 1455
Glycemic control
cognitive function and, 656
microalbuminuria and, 313
socioeconomic status and, 423
sucralose and, 1004
symptoms and well-being and, 204
Glycemic targets, 91
Great toe, amputation of, foot deformities and ulcers after, 165
Guar gum, in enteral feeding, 899

H

HbA_{1c}
capillary
collection of, at home, 1307
on filter paper, 142
rapid testing of, in community, 764
sulfonamide-induced hemolysis and, 775
threshold of, for microangiopathy risk, 183
Health care, structure and costs of, in Finland, 494
Health maintenance organization, diabetic care in, 601, 786, 1169
Heart
mass of, calcium and, 1393
regional sympathetic denervation of, 1083
Hemodialysis
LDL apheresis and oxidation in, 1103
smoking and, 625
survival during, 1333
Hemodynamic response, to arginine, metformin and, 934
Hemoglobin. *See also* HbA_{1c}
glycated. *See* Glycated hemoglobin (GHb)
Hemolysis, sulfonamide-induced, HbA_{1c} levels and, 775
Hepatitis C virus, prevalence of, in diabetic patients, 998
Hispanic subjects, amputation incidence and proportion in, 48
HLA-DQB1, IDDM risk and, 795
HMO, diabetic care in, 601, 786, 1169
Homeostasis model assessment (HOMA), prospective analysis of, 1138
Hormone replacement therapy, plasma lipids and, in postmenopausal women, 480
Hospital, admission to, for children with IDDM, 431
Hyperbaric oxygen therapy, for foot ulceration, 1338
Hyperglycemia
calcium and, 1393
cardiovascular nerve function and, in normal subjects, 880
lispro vs. regular insulin in, 1426
Hyperglycemic clamp. *See* Clamp technique
Hyperinsulinemia
bone mineral density and, 1388
dense LDL and, 629
in nondiabetic Asian subjects, 39
Hyperkalemia
orange juice–induced, 1457
reversible, ACE inhibitors and, 781
Hypertension
left ventricular wall motion abnormality in, 887
mortality rate and, 305
nephropathy and, 401
Hypertriglyceridemia
fish oil for, insulin resistance and, 1207
monocyte binding and, 1122
Hypoaldosteronism, hyporeninemic, ACE inhibitors and, 781
Hypoglycemia
aging and, 544
cerebral infarction and, 1001
cortical blindness and, 272, 1001
counterregulatory, sex differences in, 269
dietary carbohydrates and, 498
home blood glucose meter accuracy in, 1412
in IDDM, 98
insulin infusion and, 324, 780
in intensive insulin therapy, frequency of, 181
Hypotension, orthostatic, 542

I

IDDM
adult-onset, immunogenetic markers in, 241
after gestational diabetes, 653
antroduodenal motility in, 21
in child. *See* Children with IDDM
childhood-onset, time-space clustering of date at birth in, 328
complement C4 polymorphism and, 53
erectile dysfunction in, 133
evoked potentials in, 1220
GLP-I in, 580
hypoglycemia in, 98
incidence of
in Denmark, 801
in Italy, 70, 1454
of long duration, renal function in, 249
milk and, 379
prevention of, 96
prognosis in, 758
microalbuminuria and, 313
recent-onset
nicotinamide for, 1357
proinsulin immunoreactivity in, 146
risk for, HLA-DQB1 genotype and, 795
seasonal variation in, 1035
treatment of, 96
Ileus, acarbose and, 1033
Immunoglobulin A, in children with IDDM, 779
Immunology, of IDDM, 550
Infant formula, bovine serum albumin peptide in, 1364
Infection
after cesarean section, 597
from *Eikenella corrodens*, 1011
on foot, antimicrobials for, 638
Inositol, urinary, insulin resistance and, 76
Inpatient diabetes management, 90
Insulin
antibodies and autoantibodies to, in recent-onset IDDM, 146
endothelin-1 concentration and, 504
lipoatrophy induced by, 255, 1283, 1289
in postmenopausal women, 333
smoking and, 1229
Insulin antibodies, in pregnancy, metabolic control and, 979
Insulin infusion
for autonomic neuropathy, 90
complications with, 384
hypoglycemia in, 324, 780
pump compatibility in, 812

underdelivery in, 812
Insulin receptor substrate 1 gene, NIDDM and, 446
Insulin resistance
acanthosis nigricans and, 885
atherosclerosis and, 274
body fat distribution and, 287, 292, 920
candidate genes for, 396
in coronary artery disease, 1
dyslipidemia and, 387, 390
fatty acids and, 394
fish oil and, 1207
maternal diabetes effect on, 822
miglitol and, 559
upper-body fat and, 920
urinary *myo-* to *chiro*-inositol ratio and, 76
Insulin response, of nondiabetic Mexican-American subjects, 67
Insulin secretion, metformin and, 781
Insulin therapy, 784. *See also* Insulin infusion; Lispro
administration of, 908
dosage of, measurement of, by caretakers of children with IDDM, 56
in elderly patient, 1326
injection site of
in child, 1434
lispro vs. regular insulin in, 1437
intensive. *See* Intensive insulin therapy
in kidney/islet transplant patient, 236
lispro vs.
in incidental hyperglycemia, 1426
injection site and, 1437
metformin with, 671
new forms of, 550
for NIDDM, intraperitoneal vs. subcutaneous, 1237
subcutaneous vs. intramuscular injection of, in child, 1434
10-year study of, 744
Intensive insulin therapy
after oral agent failure, in NIDDM, 896
hypoglycemic episodes in, frequency of, 181
quality of life and, 195
IRS-1 (insulin receptor substrate-1) gene, NIDDM and, 446
Islet cell. *See also* β-cell
hormones in, glipizide and, 883
Islet cell amyloidosis, in congenital generalized lipodystrophy, 28
Islet cell antibodies
cardiovascular risk and, 60
in children with IDDM, 1452
proinsulin secretion and, 659
vaccines and, in offspring of diabetic parents, 1456
Islet cell transplantation, insulin therapy after, 236
Italy
albuminuria in, 43
IDDM incidence in, 1454
in children, 70

J

Japanese children, with IDDM, antibodies to bovine serum albumin in, 1308
Japanese people
IDDM in, prognosis of, 758
NIDDM in
ACE gene polymorphism in, albuminuria and, 1420
β_3-adrenergic receptor in, genetic variation in, 271, 1034
glucagon receptor mutation in, 546
obesity and ketoacidosis in, 671

K

Ketoacidosis
brain dysfunction in, 1455
obesity and, 671
Ketonuria, captopril and, 673
Kidney transplantation
cholesteryl ester transfer and, 1108
insulin therapy after, 236
in Pima Indians, 1333
Koreans, adult-onset IDDM in, immunogenetic markers in, 241

L

Labor, premature, β-sympathomimetic therapy for, 899
Lactic acidosis, phenformin and, 1449
Latex allergy, 184, 546
LDL. *See* Low density lipoprotein
Linseed oil, NIDDM control and, 463
Lipid(s), in serum
gestational diabetes and, 1351
retinopathy and, 1291
Lipid metabolism
insulin resistance and, 387, 390
metformin effect on, 1185
in NIDDM and IGT patients, 365
in postmenopausal women, hormone replacement therapy and, 480
Lipid peroxidation, circulating products of, smoking and, 1233
Lipoatrophy, insulin-induced, 255, 1283, 1289
Lipodystrophy, congenital generalized, islet amyloidosis in, 28
Lipoprotein. *See* Low density lipoprotein
Lipoprotein(a)
in African-Americans with NIDDM, 1129
nephropathy and, 1036
Lispro
postprandial blood glucose control and, 945
regular insulin vs.
in incidental hyperglycemia, 1426
injection site and, 1437
Liver toxicity, of glibenclamide, 385
Locus of control, physical activity and, 1118
Low-density lipoprotein
oxidation of, apheresis and, 1103
visceral fat and hyperinsulinemia and, 629
Lower extremity. *See also* Foot *entries*
amputation of
incidence of, 1006
in Nauruans, 710
risk factors for, 95, 607

M

Macroalbuminuria. *See also* Albuminuria
in NIDDM, in Italian subjects, 43
Malnutrition
slowly progressive IDDM in, 178
in tropical countries, 1014
Manitoba, IDDM epidemiology, 807
Maternal diabetes, offspring insulin resistance and, 822
Mauritania, diabetes prevalence in, 761
Menopause. *See* Postmenopausal women
Metabolic control, in children with IDDM, 318
Metabolic syndrome
in African-Americans, 414
in Hong Kong Chinese, 953
Metformin, 1039
adipose tissue metabolism and, 160
as adjuvant to sulfonylurea therapy, 252
cardiovascular risk and, 64
exogenous insulin with, 671
glucose and lipid metabolism and, 1185
insulin secretion and, 781
peripheral blood flow and, 160
upper-body fat–associated insulin resistance and, 920
and vascular responses to arginine, 934
Methane-producing status, glucose intolerance and, 549
Mexican-American subjects, nondiabetic, insulin response of, 67
Mexico City Diabetes Study, 1138
Michigan Neuropathy Screening Instrument, reproducibility of, 904
MICRO-HOPE Study, 1225
Microalbuminuria
in adolescents with IDDM, 369
erythrocyte Na^+/H^+ exchange and, 995
glycemic control and prognosis in, 313
in NIDDM, 79
in Italian subjects, 43
serum sialic acid and, 130, 435
Microangiopathy, HbA_{1c} threshold for, 183
Miglitol, insulin sensitivity and, 559
Milk
bovine serum albumin peptide in, 1364
IDDM and, 379
Mitochondria, genetic mutation in
of aldehyde dehydrogenase, 1423
α- and β-cell dysfunction and, 1166
of tRNA, 1304
Mitochondrial diabetes, neuroimaging in, 739
Mitral valve prolapse, prevalence of, 672
MODY3 locus on chromosome 1 2q, diabetic complications and, 915
Monitoring of blood glucose, 908. *See also* Glucose meter
accuracy of, 903, 1412
laboratory comparison with, 168
altitude and, 1430
in pregnancy, meter accuracy in, 268
standardization of, 676
triglycerides in, 1305
Monocyte, binding of, to endothelial cells, hypertriglyceridemia and, 1122
Mortality. *See* Death
Myocardial infarction, acute, thrombolytic therapy for, 1135
Myocarditis, in IDDM, 375

N

Na^+/H^+ exchange, in erythrocytes, microalbuminuria and, 995
Na^+-K^+-ATPase, neuropathy and, 564
Nauruans, lower-extremity amputation in, 710
Neonatal diabetes, DQB1 typing and, 1308
Nephropathy, 1038. *See also* Hemodialysis
ACE inhibitors and vitamin E and, 1225
apolipoprotein(a) level in, 1382
captopril for, economics of, 1051
in Europe vs. U.S., 219
fish oil in, 1214
hypertension and, 401
lipoprotein(a) and apolipoprotein(a) phenotypes and, 1036
in long-duration IDDM, 249
mortality from, in Pima Indians, 777, 779
orange juice–induced hyperkalemia in, 1457
platelet calcium in, 1062
pregnancy and, 1067

renal replacement therapy in, survival during, 1333
serum sialic acid and, 130, 435
socioeconomic status and, 423
tissue factor pathway inhibitor activity in, 441
Netherlands
diabetes incidence in, 214
hospital admissions in, for children with IDDM, 431
Neuroimaging, in mitochondrial diabetes, 739
Neuropathy
autonomic. *See* Autonomic neuropathy
cardiac
coronary artery disease symptoms and, 231
hyperglycemia and, in normal subjects, 880
Michigan Neuropathy Screening Instrument reproducibility in, 904
Na^+-K^+-ATPase and, 564
pathophysiology of, 553
peripheral
postural rearrangement in, 372
tolrestat for, 1091
regional sympathetic, cardiac, 1083
urinary albumin excretion and, 1243
Nicotinamide, for recent-onset IDDM, 1357
NIDDM
after gestational diabetes, 653
brain function in, 361
in child. *See* Children with NIDDM
depression and, 1097
dyslipoproteinemia in, GLP-I for, 1200
in elderly, 1320, 1326
etiology of, 1311
genetic markers of, 864
high–β-glucan cereals and, 831
IRS-1 gene and, 446
in Italian subjects, micro- and macroalbuminuria in, 43
oral agent failure in, intensive insulin therapy after, 896
prevalence of, 547
prevention of, 785, 972
recent-onset, altered taste sensation in, 768
serum sialic acid and albuminuria in, 130
treatment of, 295, 784, 906, 1311
Nutrition. *See* Diet
Nutrition therapy
enteral, guar gum in, 899
fat replacers in, 1294, 1302
n-3 fatty acids, NIDDM control and, 463

O

Obesity, 1311
glucose and insulin metabolism in, exercise intensity and, 341
insulin resistance and, 287, 292
ketoacidosis and, 671
pathogenesis of, 551
treatment of, 676. *See also* Weight loss
visceral. *See* Visceral fat
Orange juice, hyperkalemia induced by, 1457
Osteomyelitis, conservative surgery for, 1257
Outpatient diabetic care, in HMO, 601
Oxidation, LDL apheresis and, 1103
Oxidative stress
exercise-induced, 569
vascular complications and, 257, 1165
Oxygen therapy, hyperbaric, for foot ulceration, 1338

P

Pain, during cold pressor test, 722
Pancreas
β-cell function in, aging and, 8
size of, in children with IDDM, 777
Pancreatic carcinoma, in Sardinia, 184
Pancreatic diabetes, fibrocalculous, 1274
Pancreatic polypeptide, response of, to autonomic neuropathy and food, 778
Pancreatic transplantation
cholesteryl ester transfer and, 1108
diet after, 735
prevalence of, 97
Parental diabetes. *See also* Familial diabetes
offspring diabetes and, 822, 827, 1456
Patient participation, regimen adherence and, 1153
Percutaneous transluminal balloon angioplasty, for foot ulcer, 1261
Peripheral blood flow, metformin and, 160
Peripheral neuropathy
postural rearrangement in, 372
tolrestat for, 1091
Peripheral vascular resistance, exercise and, in young IDDM patients, 1286
Peripheral vasomotion, impaired, 715
Phenformin, lactic acidosis and, 1449
Physical activity, locus of control and, 1118
Pima Indians
arterial calcification in, 968
foot amputation in, 704
mortality in
causes of, 107
from nephropathy, 777, 779
renal replacement therapy in, 1333
Platelet calcium, in end-stage renal failure, 1062
Postmenopausal women
glucose and insulin levels in, 333
gluose intolerance in, androgen activity and, 1399
hormone replacement in, plasma lipids and, 480
Posture, in peripheral neuropathy, 372
Pre-conception care
congenital malformations and miscarriage and, 514
cost benefit of, 384
Pregnancy. *See also* Gestational diabetes mellitus; Pre-conception care
blood glucose meters in, accuracy of, 268, 1031
in diabetic woman, insulin antibodies in, 979
glycosylated hemoglobin in, 1455
nephropathy and, 1067
Prevalence studies
of albuminuria, 486
of amputation
in African-American subjects, 48
in minority subjects, 48
of coronary heart disease risk, in Australian Aborigines, 1269
of diabetes
aging and, 114, 1279
in Egyptian deserts, 92
in Manitoba, 807
in Mauritania, 761
in Netherlands, 214
in northern Sudan, 1126
parental history and, 827, 1456
of erectile dysfunction, 133
of glucose intolerance, 663
in Rio de Janeiro, 663
of hepatitis C virus, 998
HOMA model in, 1138
of IDDM
in Denmark, 801
in Italy, 70, 1454
of mitral valve prolapse, 672
of NIDDM, 547
of pancreatic transplantation, 97
of pulmonary function, 1441
of retinopathy, 1045, 1375
Prevention trials, in NIDDM, 972
Prognosis of IDDM, microalbuminuria and, 313
Progressive IDDM, GAD antibodies in, 1031
Proinsulin immunoreactivity, in recent-onset IDDM, 146
Proinsulin secretion, islet cell antibodies and, 659
Proinsulin-to-insulin ratio, after gestational diabetes, predictive value of, 17
Protein turnover, in gestational diabetes, 591
Proteinuria, mortality rate and, 305
Psychiatric disorders, in children with IDDM, 318
PTA (percutaneous transluminal balloon angioplasty), for foot ulcer, 1261
Pulmonary function, in elderly patients, glucose level and, 1441
Pupillary response, disease duration and, 960

Q

QT interval, sudden death and, 1010
Quality of life, intensive therapy and, 195

R

Rancho Bernardo Study, 1441
Recent-onset IDDM
nicotinamide treatment for, 1357
proinsulin immunoreactivity in, 146
Recent-onset NIDDM, altered taste sensation in, 768
Red blood cell, Na-Li countertransport activity in, in non-nephropathic diabetic twins, 32
Referrals, to rehabilitation service, for patients with visual loss, 175
Rehabilitation, of patients with visual loss, 175, 902
Renal disease. *See* Nephropathy
Renal replacement therapy, survival during, 1333
Research, policy advocacy and, 1165
Retinal artery, occlusion of, in antiphospholipid syndrome, 92
Retinopathy. *See also* Visual loss
epidemiological studies of, 552
as predictor of coronary artery disease, 1445
serum lipids and, 1291
socioeconomic status and, 423
urinary albumin excretion and, 1243
VA study of, 1375
Wisconsin epidemiological study of, 1045
Rheological response, to arginine, metformin and, 934
Rio de Janeiro, glucose intolerance prevalence in, 663

S

Scintigraphy
dipyridamole thallium myocardial, of vascular surgery patient, 355
exercise thallium 201, false-positive, 185
Screening, for gestational diabetes mellitus, 12
Seasonal variation, in IDDM, 1035

Self-management
in children, 119
dietary, office-based intervention in, 835
Sex hormones, and death from ischemic heart disease, 1045
Sialic acid, in serum
microalbuminuria and, 130, 435
nephropathy and, 130
Smoking
cardiovascular risk and, 112
circulating lipid peroxidation products and, 1233
glucose tolerance and, 112
hemodialysis survival and, 625
plasma insulin and, 1229
Socioeconomic status, diabetic complications and, 419, 423
Sodium-lithium countertransport activity, in non-nephropathic diabetic twins, 32
Sucralose, glycemic effect of, 1004
Sucrose, dietary, metabolic effects of, 1249
Sudan, northern, diabetes prevalence in, 1126
Sulfonamides, hemolysis induced by, HbA_{1c} levels and, 775
Sulfonylurea therapy
acarbose vs. metformin as adjuvant to, 252
failure of, metformin effect on glucose and lipid metabolism in, 1185
glimepiride response after, 849
liver toxicity of, 385
Supplies for diabetes care, cost of, 1416
Sympathetic neuropathy, cardiac, 1083
β-sympathomimetic therapy, for premature labor, 899
Syndrome X, cardiovascular risk and, 275

T

T-cell activation, in prediabetic twins, 1177
Taiwanese, NIDDM in, IRS-1 gene and, 446
Taste sensation, alterations in, 768
Temperature, glucose meter measurements and, 771
TGF (transforming growth factor)-β1, plasma elevation of, in NIDDM, 1113
Thailand, GAD antibody in, 674
Thrombolytic therapy, for acute myocardial infarction, 1135
Thyroxine-binding globulin, in pubertal diabetic children, 246
Tissue factor pathway inhibitor, in nephropathy, 441
Toe, great, amputation of, foot deformities and ulcers after, 165
Tolrestat, for peripheral neuropathy, 1091
Torsade de pointes, long QT interval and, 1010
Transforming growth factor-β1, plasma elevation of, in NIDDM, 1113
Transplantation, of pancreas. *See* Pancreatic transplantation
Triglyceride monitoring, 1305
Troglitazone, for NIDDM, 151
Tropics, malnutrition in, 1014
Tumor necrosis factor-α, adipocyte dedifferentiation and, 1283
Twin(s)
diabetic, non-nephropathic, erythrocyte Na-Li countertransport activity in, 32
prediabetic, $CD8^+$ T-cell activation in, 1177

U

Ulcers, on foot. *See* Foot, ulceration of
Uremia, platelet calcium in, 1062

V

Vaccines, in offspring of diabetic parents, islet cell antibodies and, 1456
Vascular disease. *See also* Cardiovascular *entries*
complement C4 polymorphism and, 53
mortality and, 305
oxidative stress and, 257, 1165
in Pima Indians, 968
Vascular endothelial growth factor, in aqueous humor, rubeotic glaucoma and, 1306
Vascular surgery, dipyridamole thallium myocardial scintigraphy before, 355
Vasomotion, peripheral, impaired, 715
VEGF (vascular endothelial growth factor), in aqueous humor, rubeotic glaucoma and, 1306
Ventricle, left, wall motion abnormality in, 887
Veterans Affairs Glycemic Control and Complications in Type II Diabetes Study, 1357
Victoria, Australia, GHb assay variations in, 730
Visceral fat
dense LDL and, 629
insulin resistance and, 287, 292
relation of, to subcutaneous adipose tissue distribution and insulin and glucose levels, 1404
7-year changes in, 983
Visual loss. *See also* Retinopathy
cortical, 272, 1001
patient rehabilitation in, 175, 902
Visually evoked potentials, in IDDM, 1220
Vitamin E, renal and cardiovascular effects of, 1225

W

Walking, postprandial, gastric emptying and, 1306
Wanigela people of Papua New Guinea, diet of, 457
Weight loss. *See also* Obesity
behavioral program for, 409
bromocriptine (Ergoset) for, 667
strategies for, 613
Well-being, glycemic control and, 204
Wisconsin Epidemiologic Study of Diabetic Retinopathy, 1045
Women, postmenopausal. *See* Postmenopausal women
Women with diabetes, pregnancy in. *See* Pregnancy, in diabetic woman

Y

Young adults with IDDM
anti–bovine serum albumin antibodies in, 126
peripheral vascular resistance in, exercise and, 1286

Z

Zinc deficiency, childhood IDDM and, 873

Author Index

A

Abate, N., 292
Åberg, H., 992
Abo, K., 1010
Abourizk, N.N., 271
Abraira, C., 1375
Acampora, R., 934
Acton, R.T., 672
Adalar, N., 252
Ader, M., 1018
Adojaan, B., 1452
Adorisio, E., 70
Agata, T., 758
Aguilar-Diosdado, M., 674
Aguilar-Salinas, C.A., 94
Ahmed, M., 60
Ahonen, A., 231
Ahrén, B., 843, 1399
Airaksinen, K.E.J., 231
Aizawa, T., 1033
Akanuma, Y., 151
Åkerblom, H.K., 795, 1452
Akita, H., 1036
Akkermans, L.M.A., 21
Albert, S.G., 175, 883
Alberti, K.G.M.M., 900
Albertsson, P., 698
Aldeghi, A., 1338
Ali, V.M., 39
Allen, M.E., 268
Allison, D.B., 1004
Almēr, L.-O., 142
Alroy, G., 385
Alviggi, L., 1177
Alzaid, A.A., 79
American Diabetes Association, 1302
Amodeo, B.M., 1454
Anderson, K., 807
Andersson, O.K., 160
Anding, R., 613
André, P., 920
Anglin, K., 409
Annuzzi, G., 1207
Arab, M., 92
Argenziano, A., 779
Ariza, C.R., 112
Armenian, H., 1097
Arnqvist, H.J., 313, 726
Aro, S., 494
Asahina, T., 739, 1304, 1423
Ashry, H.R., 48
Ashworth, L.A., 900
Atalay, M., 569
Atherosclerosis Risk in Communities Study Investigators, 414, 480
Atkison, P.R., 236
Atlan-Gepner, C., 1283
Atsumi, Y., 739, 1304, 1423
Aubry, W., 90
Auinger, M., 53
Awata, T., 272
Azulay, J.-P., 564

B

Baba, S., 778
Baba, T., 1420
BABY-DIAB Participants, 1456
Bagdade, J.D., 1108
Baleynaud, S., 761
Balkau, B., 822
Barbagallo, M., 1393
Bard, J.-M., 920
Bargero, G., 43
Barinas, E., 1344
Baron, A.D., 591
Barrett-Connor, E., 333, 450, 1388, 1441
Barriocanal, L.A., 900
Bartelds, A.I.M., 214
Bartholomew, D., 903
Bastyr, E.J., III, 546
Basu, S., 48
Bauduceau, B., 761
Bax, G., 904
Bayraktar, M., 252
Becker, D.J., 1370
Behme, M.T., 236
Beischer, N.A., 653
Belarbi, N., 1434
Bell, D.S.H., 185, 509, 672, 779
Bellini, C., 504
Belloni, C., 979
Benali, K., 1434
Benda, N., 722
Benedetti, M.M., 927
Bennett, P.H., 107, 777, 968, 972, 1333
Benzi, L., 781
Beregszaszi, M., 1434
Beretta, A., 979
Berger, M., 1006
Bergman, R.N., 1018
Bergström, A., 726
Bernal, J.E., 900
Bernbaum, M., 175, 883
Berne, C., 1126
Bernert, G., 1220
Bessman, A.N., 95
Best, J.D., 1018
Bianchi, R., 1437
Biesenbach, G., 625
Bigard, A.X., 1430
BIGPRO Study Group, 920
Bilo, H.J.G., 542
Binder, C., 17, 146
Birnbacher, R., 1220
Bjørbæk, C., 396
Blanchard, J.F., 807
Bloomgarden, Z.T., 96, 295, 401, 550, 676, 784, 906, 1038, 1168, 1311, 1459
Boccio, V., 915
Bode, B.W., 324
Boden, G., 394
Boerwinkle, E., 864
Boesiger, P., 1075
Bognetti, E.R.M., 1307
Bojestig, M., 313
Bolli, G., 945
Bonacci, W., 1308
Bongrand, P., 1283
Bonnet, F., 781
Bonora, E., 211
Borovicka, J., 1075
Borra, M., 43
Bosch, J., 1225
Bots, M.L., 157
Bouchard, C., 983
Boudreau, D.A., 1129
Bouteleau, S., 812
Bouter, L.M., 204
Bovikov, V., 182
Brambilla, G., 1261
Brancati, F.L., 414, 480
Braun, B., 472
Brechtel, G., 591
Bressan, F., 211
Briceño, I., 900
Bringer, J., 812
Brorsson, B., 992
Brown, S.A., 613
Browne, P.D., 1357
Brue, T., 1283
Brunetti, P., 945
Brunner, G.A., 1412
Bruno, C., 1308
Bruno, E., 372
Bruno, G., 43
Brunzell, J., 92
Bubb, J., 648
Buchanan, T.A., 514
Bülow, I., 1135
Burchfiel, C.M., 587
Buse, J., 864
Bush, T., 333
Buzzetti, R., 70

C

Cai, J., 480
Calia, P., 1261, 1338
Calvert, D., 1305
Calvi, V., 43
Campagnoli, P., 1338
Campbell, D., 355
Campbell, L.V., 575, 1033
Canani, L.H., 171
Capani, F., 927
Carey, D.G., 1033
Carinci, F., 927, 1091
Carter, A.M., 1265
Carter, J.S., 764
Cassone-Faldetta, M., 226
Castagne, C., 761
Castiglioni, M., 979
Cathelineau, G., 1430
Cavaliere, D., 927
Cavallo-Perin, P., 43
Cecchetti, P., 781
Ceriello, A., 257
Cerimele, B., 1437
Cervera, R., 94
Chalmers, J., 876
Chan, A.Y.W., 953
Chan, J.C.N., 953
Chandalia, M., 28
Chantelau, E., 1165
Chapel, H., 246
Chari, S.T., 1274
Charles, M.A., 920
Charpentier, G., 915
Chaturvedi, N., 423
Chen, J.-W., 130
Cheung, J.C.K., 953
Chew, E.Y., 1291
Chiara, A., 777
Chiasson, J.-L., 1190
Chiba, H., 1036
Childhood Diabetes in Finland (DiMe) Study Group, 795
Chisholm, D.J., 575, 1033
Chiu, K.C., 864
Chiumello, G., 1307
Choux, R., 1283
Christensen, P.D., 1135
Chuang, L.-M., 446
Chung Lu, H., 1449
Ciardullo, A.V., 498
Ciccarone, A.M., 781
Cincotta, A.H., 667
Citron, D.M., 638
Clandinin, M.T., 463

Clark, L., 56
Clarke, W.L., 269
Cleary, P., 180
Cleave, B., 168
Cockrama, C.S., 953
Cogliardi, A., 1307
Cohen, J.-M., 920
Cohen, M.C., 355
Cohen, R.M., 1190
Colditz, G.A., 12
Collaborative Study Group, 1051
Colwell, J., 1375
Colwell, J.A., 896
Combs, C.A., 514
Comerci, M.D., 70
Comstock, J., 1375
Conget, I., 94, 255
Connolly, V.M., 419
Connors, M.H., 246
Cook, C.B., 1129
Cooperative Group for the Study of Diabetes Prevalence in Rio de Janeiro, 663
Corbellini, M., 211
Cornell, J.E., 1416
Costalat, G., 812
Cotellessa, M., 1308
Counsell, C., 768
Cox, D.J., 269
Craen, M., 1286
Craig, J.W., 76
Crelier, G., 1075
Creutzfeldt, W.O.C., 580
Cristallo, M., 384
Cruickshanks, K.J., 135, 744, 827
Cruz, J., 864
Csako, G., 673
Cull, C.A., 182
Cummings, J.F.R., 876
Curb, J.D., 587
Czernichow, P., 1434

D

Dahlquist, G., 328, 369, 873
Danan, J.-P., 1257
Danne, T., 183, 901
d'Annunzio, G., 777
Dargaville, R.M., 653
DaSilva, S.G., 341
Davidson, M.B., 601, 899
Davidson, P.C., 324
Davis, D., 648
de Azevedo, M.J., 171
De Cicco, A.L., 70
de Courten, M., 968
De Felice, E., 1454
De Filippo, G., 779
de Groot, R.R.M., 431
de Marco, R., 211
De Mattia, G., 226, 504
De Neeling, J.N.D., 204
De Nino, L.A., 1416
De Rosa, N., 934
De Wolf, D., 1286
Deambrogio, P., 43
Dean, H., 807
Deckert, M., 130
Deckert, T., 435
DeFronzo, R.A., 864
Del Sindaco, P., 945
Delisle, H., 822
Denne, S.C., 591
Depew, N., 807
D'Errico, N., 43
Desideri, G., 504
Després, J.-P., 629, 983
Di Girolamo, S., 372
Di Marino, L., 1207
Di Vincenzo, A., 945
Diabetes Control Complications Trial Research Group, 195
Diabetes Epidemiology Research International Study Group, 758
DiMatteo, M.R., 1153
Dinesen, B., 146, 183, 726
Doelman, C.J.A., 542
Dooley, S.L., 1067
Dorchy, H., 1165
Dorman, J., 241
Douce, P., 1430
Dowse, G.K., 457, 710
Dozio, N., 979
Drash, A., 318, 1319
Drewes, C., 1113
Duarte, A.L., 1249
Dubrey, S.W., 32
Ducorps, M., 761
Duncan, B.B., 414
Dunger, D.B., 246
Dunn, F.L., 384
Dupre, J., 236
Duvallet, A., 1430
Dyerberg, J., 1382

E

Early Treatment Diabetic Retinopathy Study Research Group, 1291
Eaton, W W., 1097
Ebeling, P., 689
Edelman, D., 755
Edelman, S.V., 1237
Edelstein, S., 450
Edwards, P.R., 246
Efendic, S., 857, 1200
Ehrmann, D.A., 864
Eisenhuber, E., 1455
Ekberg, G., 142
Ekoé, J.-M., 822
Elahi, D., 278
Elbagir, M.N., 1126
Elbein, S.C., 507, 864
Elberink, J.N.G.O., 542
Elin, R.J., 673
Elixhauser, A., 384
Elks, M.L., 271
Elliott, T., 1320
Elmahadi, E.M.A., 1126
El-Sewi, F., 92
Eltom, M.A., 1126
Emanuele, N., 1375
Emanuelsson, H., 698
Epifano, L., 945
Erkelens, D.W., 1426, 1437
Errera, A., 1279
Eschwege, E., 822, 920
Eshøj, O., 801
Espeland, M.A., 333
Espinosa-Campos, J., 1185
Estacio, R.O., 1243
EURODIAB IDDM Complications Study Group, 423, 689
Evadiac Study Group, 780

F

Fabreguettes, C., 564
Faccini, G., 1233
Fagherazzi, C., 904
Faglia, E., 1261, 1338
Faleiro, R.M., 656
Fan, K., 1457
Fanghänel, G., 1185
Farnarier, C., 1283
Favales, F., 1261, 1338
Fazel, A., 771
Fedele, D., 904
Fernandes, R.J., 968
Fernandez-Fernandez, F., 94
Fernlund, P., 60
Ferreira, S.R.G., 126
Ferri, C., 226, 504
Ferris, F., 1091
Ferris, F.L., III, 1291
Finegood, D.T., 463
Firth, L.M., 1051
Fog, L., 1135
Folli, F., 1062
Folsom, A.R., 480
Fontbonne, A., 920
Ford, D.E., 1097
Fortier, L., 1404
Franco, L.J., 663
Franz, M., 1294
Franzese, A., 779
Fraser, R.J., 880
Frati, A.C., 112
Freilinger, M., 1220
Frette, C., 1441
Fried, M., 1075
Friedman, R., 171
Frier, B.M., 768
Frisbie, K., 735
Froguel, P., 915
Fujimoto, W., 587, 864
Fujisawa, T., 544
Fukumura, Y., 940
Fuller, J.H., 219, 305, 423
Furler, S.M., 575

G

Gaber, O., 1108
Gall, M.-A., 130
Galli, L., 1062
Gallo, J., 1097
Gallus, G., 1279
Garancini, M.P., 1279
Garg, A., 28, 274, 387, 1142
Gasparini, N., 779
Gault, A., 1269
Gauthier, J.-F., 1283
Gautier, J.-F., 1430
Gelberg, L., 1153
Genescà, J., 998
Gentzkow, G.D., 350
Genuth, S., 180
Gerstein, H.C., 1225
Gfrerer, R.J., 1412
Giacco, R., 498
Giacomini, P.G., 372
Giampietro, O., 995
Giani, G., 1006
Giannarelli, R., 781
Gibert-Boulet, F., 812
Gijsen, R., 214
Gilbert, R.E., 730
Gilliland, S.S., 764
Giovannini, C., 70
Giugliano, D., 257, 934
Giunta, R., 934
Glasgow, R.E., 835, 1165

Glimepiride Protocol #201 Study Group, 849
Glimepiride Study Group, 1194
Gobbi, C., 1279
Gold, A.E., 1001
Goldberg, R.B., 849
Goldstein, D.E., 726
Goldstein, E.J.C., 638
Golichowski, A.M., 591
Golin, C.E., 1153
Gómez, A., 900
Gomis, R., 94, 255
Gonder-Frederick, L.A., 269
Gonzalez, C., 1138
Goodall, I., 730
Goodman, S.N., 56
Gosling, R.G., 501
Goss, F.L., 341
Goto, Y., 1304
Gottsäter, A., 60, 659
Gould, C., 876
Gracey, M., 472
Graepel, J.G., 1091
Grandmottet, P., 920
Grant, P.J., 64, 1265
Green, A., 801
Green, G.M., 468
Greendale, G., 333
Greene, M.F., 597
Greene, T., 704
Gregg, E.W., 1118
Griffiths, R.D., 179
Grimaldi, A., 1257
Grimm, G., 1455
Grob, J.-J., 1283
Grobbee, D.E., 157
Grootenhuis, P.A., 204
Gross, J.L., 171
Guan, D., 468
Gudbjörnsdóttir, H.S., 160
Guenifi, A., 857
Guerci, B., 780
Guerrero-Romero, F., 547
Gügolz, E., 831
Gupta, R.K., 1393
Gutniak, M., 1200
Gutniak, M.K., 843, 857

H

Ha Van, G., 1257
Haastert, B., 1006
Haffner, S.M., 67, 274, 275, 1045, 1138, 1445
Hagberg, J.M., 341
Haglid, M., 698
Haglund, B., 873
Hammer, H.F., 1306
Hampson, S.E., 835
Hamsten, A., 1200
Hanaire-Broutin, H., 780
Hanatani, M., 1306
Handa, M., 1423
Hanis, C.L., 864
Hänninen, O., 569
Hansen, B.V., 1214, 1382
Hansen, H.-H.T., 1135
Hanson, R.L., 968, 972, 1333
Hanson, U., 17
Hantsch, C.E., 1067
Hanuschak, L.N., 671
Hara, T., 642
Hara, Y., 1
Harano, Y., 1
Hardin, H., 722
Hardman, T.C., 32
Hards, L., 1320
Harkless, L.B., 48
Hartling, S.G., 17, 146
Hashizume, K., 1033
Hassan, M., 1434
Hata, T., 739
Hauser, E., 1220
Hawa, M., 1177
Hayakawa, N., 375
Head, J., 305
Heeren, T., 597
Heiber, S.J., 843
Heikkila, J., 231
Heine, R.J., 204
Heiss, G., 414
Hellström, P.M., 857
Henderson, W.G., 1375
Henry, R.R., 1237
Herlitz, J., 698
Hernández, C., 998
Hershon, K.S., 350
Herva, E., 795
Higuchi, S., 1423
Hill, M.A., 715
Hill, T., 355
Hiramitsu, S., 375
Hirasing, R.A., 214, 431
Hirsch, I.B., 92
Hodge, A.M., 457
Hoekstra, J.B.L., 1426
Hoffman, B.R., 168
Hoffman, M.D., 507
Hofman, A., 157
Hofmann, V., 722
Hohman, T.C., 1091
Holleman, F., 1426
Holman, R.R., 182
Hølmer, G., 1214
Holst, J.J., 580, 843, 857
Holvey, S.M., 849
Honmura, S., 1306
Hoogerbrugge, N., 1122
Hoogwerf, B.J., 1291
HOPE Study Investigators, 1225
Hopkins, K.D., 501
Hori, M., 887
Horn, H.M., 1289
Horowitz, M., 880
Hosokawa, K., 1304
Hotta, N., 642
Hou, S.H., 1067
Hough, B.S., 119
Houston, C.A., 764
Hoven, R.A.R.A., 1426
Hozumi, T., 1010
Hramiak, I., 236
Huang, B., 587
Hudson, R., 1404
Hui, S.-P., 1036
Huikuri, H.V., 231
Huma, Z., 1011
Hummel, M., 1456
Humphrey, A.R.G., 710
Hunter, D.J., 12
Huss, E., 1108

I

Iafusco, D., 1454
Idzior-Walus, B., 689
Iitiä, A., 795
Ikebuchi, M., 1
Ikegami, H., 544
Ilonen, J., 795
Infusaid Multicenter Implantable Insulin Pump Study Group, 384
Iniestra, F., 112
Inoue, I., 1103
Inui, A., 778
Iovine, C., 1207
Irsigler, K., 53
Ishida, Y., 1010
Ishii, C., 8
Isnard, F., 920
Ito, M., 74, 902
Ito, Y., 8
Itoh, M., 375
Itoh, Y., 375
Iwamoto, Y., 151
Iwasaki, S.D., 350
Iyengar, S., 318

J

Jaap, A.J., 1289
Jackson, T., 184
Jacobs, M.L., 1122
Jacobson, A., 648
Jacques-Apostol, D., 812
Jaffiol, C., 812
Jain, S.K., 39
Jannasch, K., 648
Jansa, M., 255
Jansson, P.-A.E., 160
Jardi, R., 998
Jaruratanasirikul, S., 674
Jeandidier, N., 780
Jebbink, R.J.A., 21
Jeffcoate, W.J., 656
Jeffers, B., 1243
Jefferson, I., 246
Jenkins, A.B., 575
Jensen, J.S., 130, 435
Jeppsson, J.-O., 142
Jerntorp, P., 142
Jerums, G., 730
Joffe, B.I., 1451
Johnson, A.B., 559
Johnson-Nagel, N., 1375
Jones, H.E., 168
Jones, R.L., 501
Jongkind, J.F., 1122
Josse, R.G., 1190
Jowett, T.P., 246
Juhan-Vague, I., 920
Julian, D.M., 269
Jumpson, J., 463
Juneskans, O.T., 843
Juntti-Berggren, L., 857, 1200

K

Kadam, I.M.S., 1126
Kadowaki, H., 739
Kadowaki, T., 739
Kahn, S.E., 864, 1018
Kalits, I., 1452
Källen, B.A.J., 328
Kamado, K., 887
Kameda-Takemuara, K., 287
Kaneko, T., 151
Kang, J., 341
Kangas, T., 494
Karjalainen, J., 1452
Karlberg, B.E., 313
Karlson, B.W., 698
Karlsson, T., 698
Karn, C.A., 591

Karpe, F., 1200
Kassi, G., 945
Kasuga, M., 778
Katayama, K., 361
Katayama, S., 272, 1103
Kato, N., 8
Kato, R., 375
Katsura, Y., 1036
Kawaguchi, R., 1423
Kawakami, Y., 1306
Kawazu, S., 8
Kazakawa, M., 1308
Kazumi, T., 1010
Kelley, D.E., 341, 1237
Kelly, C., 656
Kendall, O., 807
Kennedy, E., 1138
Kerum, G., 182
Kesson, C.M., 419
Kieselhorst, K., 1370
Kikuchi, C., 1103
Kim, Y., 887
Kirk, B.A., 656
Kitabchi, A.E., 1108
Kitzmiller, J.L., 384, 514
Kjærgaard, S.C., 1135
Kjems, L.L., 146
Kjos, S., 514
Klein, B.E.K., 135, 744, 827, 1045
Klein, R., 135, 744, 827, 1045, 1375
Kleine, N., 580
Knip, M., 795, 1452
Knowler, W.C., 968, 972, 1118, 1333
Kobayashi, I., 940
Kobayashi, T., 178, 1031
Kobayashi, Y., 1308
Koch, P., 1004
Kogure, A., 1034
Koh, C.-S., 241
Koh, N., 642
Koistinen, M.J., 231
Koivisto, V.A., 494, 689
Kolb, H., 379, 1357
Konda, S., 1308
Kondo, M., 1034
König, P., 53
Kordonouri, O., 901
Kort, C., 722
Kosaka, K., 151, 1031
Kostense, P.J., 204
Kotake, M., 375
Kotani, K., 287
Koutoubi, Z., 771
Kovacs, M., 318
Kozawa, T., 1306
Kramer, J., 648
Kramer, L., 1455
Kretchmer, N., 472
Krim, E., 899
Kriska, A.M., 1118
Kritz-Silverstein, D., 333, 1388
Krivoy, N., 385
Kromhout, D., 214
Kronenberg, F., 53
Kubori, S., 887
Kuikka, J.T., 1083
Kullberg, C.E., 726
Kunz, P., 1075
Kurita, A., 361
Kuroda, Y., 74, 902
Kurtz, D., 1437
Kusuoka, H., 887
Kuzuya, T., 151

L

Laakso, M., 494, 607, 1229, 1445
Laaksonen, D.E., 569
Labrie, F., 629
Lachin, J., 180
Lachin, J.M., 1091
Lacy, P.E., 236, 781
Lai, C.-S., 446
Lalli, C., 945
Lamarche, B., 629
Lambeth, H., 1108
Lane, S.E., 355
Lant, A.F., 32
LaPorte, R.E., 758
Larner, J., 76
Larsen, J.L., 735
Larsson, H., 843, 1399
Larsson, L., 726
Lassman-Vague, V., 780
Lau, E.M.C., 953
Laufer, I., 885
Laurenti, O., 226
Lauton, D., 812
Lavery, D.C., 165, 818
Lavery, L.A., 48, 165, 818
Lay, A., 722
Lee, H., 241
Lee, H.S., 1375
Lee, K.E., 135
Leehey, D.J., 1457
Legorreta, A.P., 601
Lehmann, E.D., 501
Lehmann, R., 1075
Lehto, S., 607, 1445
Leiter, L.A., 1190
Lemieux, S., 983
Lerman, I., 94
Leslie, R.D.G., 32, 1177
Levin, S., 1375
Levitt, N.S., 751
Levy, I., 94
Levy, J.C., 892
Lewis, E.J., 1051
Lewis, G.F., 390
Lewis, S.M., 355
Lhotta, K., 53
Lilja, B., 60
Lin, B.J., 446
Lincoln, N.B., 656
Linnaluoto, M.M.K., 231
Linscheid, T.R., 119
Lipkin, S., 350
Lipp, R.W., 1306
Lipps, J., 648
Lisius, L., 268
Little, R.R., 726, 764
Lloyd, C.E., 219
Logwin, S., 255
Lönnroth, P.N., 160
Lorber, D., 899
Lorber, D.L., 1449
Lorenz, R.A., 648
Lorini, R., 777
Lövgren, T., 795
Lu, G.Y., 587
Ludvigsson, J., 313
Ludwig, S., 807
Luft, D., 722
Lupien, P.J., 629
Luzio, S., 659

M

MacCracken, J., 184
MacFarlane, T.W., 768
Mackay, I.R., 241
Mackin, P., 249
Macleod, J.M., 249
Madl, C., 1455
Maffettone, A., 1207
Maggio, C.A., 1004
Magrini, A., 372
Malerbi, D.A., 1249
Mancini, M., 1207
Mano, T., 375
Mansfield, M.W., 1265
Manson, J.E., 12
Manzanares, J.M., 94
Marchetti, P., 781
Marfella, R., 934
Markowski, D.M., 735
Marsh, G.M., 1416
Marshall, S.M., 249, 1001
Martinelli, C., 1233
Massé, J., 1031
Matchar, D.B., 755
Mathiesen, E.R., 435
Matsuda, J., 74, 902
Matsumura, T., 178
Matsunaga, K., 1010
Matsunuma, A., 543, 547
Matsuoka, K., 739, 1304, 1423
Matsushima, M., 758
Matsuzawa, Y., 287
Matteucci, E., 995
Matthys, D., 1286
Mattock, M., 689
Matz, R., 91, 181, 782
Mavo, B., 457
Mayaudon, H., 761
Mayfield, J.A., 704
Mazzella, M., 1308
McCandless, R.R., 1416
McCanlies, E., 241
McCarthy, B., 241
McElligott, M.C., 735
McKenzie, J.M., 1370
McLeay, T., 1269
McMahan, C.A., 468
McManus, R.M., 463
McNitt, P.M., 715
Mehrotra, B., 771
Meier, A.H., 667
Meijer, R.J.G.M., 1364
Melandri, M., 1062
Meneilly, G.S., 544, 1320
Mengel, M., 350
Menheere, P.P.C.A., 1326
Menzinger, G., 372
Mesa, J., 998
Meschi, F., 1307
Metelko, Ž., 182
Metzger, B.E., 1067
Meyer, M.D., 715
Meyers-Seifer, C.H., 1351
Mezitis, N.H.E., 1004
Michael, M., 1338
Middelberg-Bisping, K., 1113
Miedema, K., 542
Miettinen, H., 67, 1138, 1445
Mihic, M., 1190
Milech, A., 663
Miller, S.A., 735
Min, H., 241
Minamide, S., 365

Miranda, W., 126
Missov, R.M., 157
Mitchell, D.C., 1370
Mittleman, M.A., 355
Miyamoto, S., 1308
Miyaoka, H., 739
Mizuno, N., 778
Mochio, S., 361
Modarelli, F., 945
Mohan, V., 1274
Mokuno, T., 375
Molitch, M.E., 1067
Moller, D.E., 396
Monauni, T., 1233
Montgomery, J., 457
Monticone, G., 372
Mooradian, A.D., 883
Moorjani, S., 629
Morabito, A., 1261, 1338
Mori, M., 365
Morimoto, S., 375
Mortensen, H.B., 183
Moses, R.G., 179, 1305, 1348
Moss, S.E., 135, 744, 827, 1045
Muchmore, D.B., 1194
Muggeo, M., 211, 689, 1233
Mukerji, P., 318
Muramatsu, T., 1423
Murase, T., 1031
Murata, A., 1308
Murata, C., 1423
Murata, K., 8
Myrup, B., 435, 441, 1214

N

Nabulsi, A.A., 480
Nadeau, A., 629, 983
Nagai, T., 365
Nagasaka, A., 375
Nagasaka, H., 1036
Nagi, D.K., 39
Naglieri, J.A., 119
Naito, E., 74, 902
Nakai, A., 375
Nakajima, K., 365
Nakajima, S., 1420
Nakamura, J., 642
Nakamura, T., 287
Nakanishi, K., 178, 1031
Nanto, S., 887
Narayan, K.M.V., 968, 972, 1118, 1455
Nathan, D., 180
Nathan, D.M., 1190
Nauck, M.A., 580
Navalesi, R., 781
Ndahimana, J., 1165
Negri, M., 70
Nelson, R.G., 107, 704, 777, 1333
Nesbit, C.A., 638
Nesto, R.W., 355
New, J.P., 249
Newfield, R.S., 1011
Newton, R.W., 876
Ni, T.-C., 1018
Nichol, H.L., 168
Nicolau, C., 255
Nicolucci, A., 904, 927, 1091
Nicotinamide Trialists, 1357
Nielsen, F.S., 1214, 1382
Nieuwenhuijzen Kruseman, A.C., 1326
Niimi, H., 1308
Nishida, M., 287
Nishii, Y., 1033
Nishimura, R., 758
Nishimura, T., 887
Niskanen, L., 569
Niskanen, L.K., 486
Nonaka, I., 1304
Nonaka, K., 671
Noritake, M., 1036
Norris, J.M., 379, 864
Nuttall, F., 1375

O

Oda, N., 375
Odawara, M., 543, 547, 739, 1165
Oddone, E.Z., 755
O'Dea, K., 1269
Odeh, M., 272
Ogihara, T., 544
Ohara, T., 887
Ohno, T., 8
Oka, Y., 1304
Okubo, M., 1031
Okuda, Y., 1306
Olack, B.J., 236
Oliveira, J.E.P., 663
Oliven, A., 272
Orchard, T.J., 219
Oriani, G., 1338
Ørskov, C., 580
Ossorio, R.C., 601
Østergaard, P.B., 441
Owen, C.L., 764
Owens, D.R., 659

P

Paauw, D.S., 92
Padma, A., 1274
Pagano, G., 43
Paiva, E.S.A., 1249
Palitzsch, K.-D., 960
Palmason, C., 1190
Palumbo, F., 1454
Pampanelli, S., 945
Paolisso, G., 257
Papiha, S.S., 900
Pardini, V.C., 126
Parikh, P.P., 1449
Parillo, M., 498
Parisi, L., 372
Park, S., 450
Park, Y., 241
Parviainen, M., 486
Parving, H.-H., 130, 1214, 1382
Pasqualini, E., 1233
Patarakijvanich, N., 674
Pathak, D.R., 764
Paul, T.L., 236
Peakman, M., 1177
Pedrinelli, R., 995
Pellegatta, F., 1062
Penttilä, I., 486
Perez, F.J.G., 94
Perez, G.E., 764
Perlman, J.A., 333
Permutt, M.A., 864
Perriello, G., 945
Perros, P., 768
Persson, B., 17
Persson, R., 142
Peters, A.L., 601, 899
Pettitt, D.J., 968, 972, 1333, 1455
Pfeiffer, A., 1113
Phelps, R.L., 1067
Phillips, W.T., 468
Piarulli, F., 904
Piccoli, A., 226
Pieber, T.R., 1412
Pieterse, A., 1451
Pigon, J., 1200
Pi-Sunyer, F.X., 1004
Pitchumoni, C.S., 1274
Pittsburgh DERI Mortality Study Group, 1344
Plotnick, L.P., 56
Plummer, S., 883
Pogue, J., 1225
Polak, M., 1434
Poloniato, A., 979
Pols, H.A.P., 157
Poretsky, L., 885
Postema, P.T.E., 1122
Powers, M.A., 1294
Pozzilli, P., 70, 1357
Pratt, L., 1097
Premalatha, G., 1274
Prendergast, J.J., 90, 350
Prisco, F., 1454
Prud'homme, D., 629, 983
Pugh, J.A., 48, 1416
Purdy, L.P., 1067
Puukka, P., 1229
Pyörälä, K., 607, 1229, 1445

Q

Quarantiello, A., 1261, 1338
Quddoos, A., 1004
Quebedeaux, T.L., 165, 818

R

Raccah, D., 564
Raffel, L.J., 864
Ramachandran, A., 1035
Rambotti, A.M., 945
Ramírez, G., 613
Rampoldi, A., 1261
Randecker, G.A., 1370
Rao, R.H., 1014
Ratner, R.E., 514
Rattarasarn, C., 674
Reeser, H.M., 431
Reiber, G.E., 704
Reijonen, H., 795
Renard, E., 780, 812
Renn, W., 722
Resnick, L.M., 1393
Reunanen, A., 494
Riccardi, G., 498, 1207
Rich-Edwards, J., 12
Ricotta, J.J., 350
Riley, L.E., 597
Ritter, M.C., 1108
Rivellese, A.A., 498, 1207
Robbins, D.C., 864
Robertson, R.J., 341
Robertson, R.P., 864
Robinson, J.G., 480
Rocher, L., 780
Rodby, R.A., 1051
Røder, M.E., 146
Rodgers, D.V., 179
Rodrigo, J.A.R., 94
Rodriguez, B.L., 587
Rodríguez-Moran, M., 547
Rodríguez-Villar, C., 94
Ronchi, P., 1062
Rondas-Colbers, G.J.W.M., 1326

Rønn, B., 435
Rönnemaa, E.M., 1229
Rönnemaa, T., 607, 1229, 1445
Rosa, S., 979
Rose, F.A., 968
Rosenstock, J., 1194
Ross, R., 1404
Rossing, P., 441, 1214, 1382
Rotter, J.I., 864
Rowley, K.G., 1269
Rowley, M., 241
Rudberg, S., 369
Russo, A., 880
Russo, E.M.K., 126
Ruwaard, D., 214, 431
Ryan, E.A., 463
Ryckenberg, K., 873

S

Sachon, C., 1257
Safar, M.E., 920
Sakakibara, F., 642
Sakamoto, K., 887
Sakane, N., 1034
Salerno, M., 779
Salinto, M., 494
Samaras, K., 575
Samols, E., 1194
Samsom, M., 21
Sánchez-Reyes, L., 1185
Sandoval-Herrera, F., 547
Santucci, A., 226, 504
Sarmiento, M., 384
Sasaki, N., 1308
Savage, S., 1243
Sawai, Y., 375
Sawin, C., 1375
Scavini, M., 384, 979
Scharp, D.W., 236, 781
Schatz, H., 1113
Scheer, W.D., 1129
Schlundt, D., 648
Schmidt, M.I., 414
Schnedl, W.J., 1306
Schneider, J., 849, 1194
Schober, E., 1220
Schölmerich, J., 960
Schrier, R.W., 1243
Schrott, H.G., 333
Schwartz, J.G., 468
Schwizer, W., 1075
Scorpiglione, N., 927
Scott, F.W., 379
Sebastiani, L., 70
Seftel, H.C., 1451
Seidl, R., 1220
Selam, J.-L., 780
Selinus, O., 873
Sels, J.-P.J.E., 1326
Sen, C.K., 569
Sergi, A., 1279
Serra, G., 1308
Shah, M., 1142
Shan, J., 450
Shannon, B.M., 1370
Shapiro, S.A., 715
Sharp, D.S., 587
Sharrett, A.R., 414
Sheedy, M.T., 653
Shibuya, H., 1036
Shigeta, Y., 151
Shima, K., 74, 902
Shimazaki, K., 375
Shimizu, H., 758
Shimizu, M., 8
Shimomura, I., 287
Shimonagata, T., 887
Shinozaki, K., 1
Shiotani, H., 1010
Shirakawa, N., 74, 902
SID-AMD Italian Study Group for the Implementation of the St. Vincent Declaration, 927
Sievers, M.L., 107, 777
Silbert, C., 1375
Silva, S.R., 56
Silveiro, S.P., 171
Simó, R., 998
Siney, H., 1257
Sjølie, A.K., 801
Sjöroos, M., 795
Smiciklas-Wright, H., 1370
Smith, R.M., 472
Smout, A.J.P.M., 21
Snehalatha, C., 1035
Snoek, F.J., 204
Snorgaard, O., 146
Solomon, C.G., 12
Sone, H., 1306
Songini, M., 185
Soo, K., 575
Soonthornpun, S., 674
Sorg, T.B., 771
Sotres, D., 1185
Spargo, R.M., 472
Spinas, G.A., 1075
Spotti, D., 1062
Stampfer, M.J., 12
Stansberry, K.B., 715, 751
Steed, D.P., 350
Steed, R.D., 324
Steiner, G., 390
Stenger, P., 184, 268, 1032
Stephenson, J., 219, 689
Stephenson, J.M., 423
Stern, M.P., 67, 333, 1138
Stevens, L., 305
Stevens, L.K., 689
Stickland, M.H., 1265
Stiller, C.R., 236
Stolarczyk, R., 885
Stolk, R.P., 157
Storlien, L.H., 1305
Stratta, R.J., 735
Straub, R.H., 960
Suematsu, M., 1423
Sugihara, S., 1308
Suminski, R.R., 341
Sundkvist, G., 60, 142, 659
Suppa, M.A., 70
Suzuki, H., 1306
Suzuki, M., 1
Suzuki, Y., 739, 1304, 1423
Swaminathan, R., 953
Szalai, J.P., 168

T

Tack, C.J.J., 775
Taglietti, M.V., 1062
Tai, T.-Y., 446
Tajima, N., 758
Takahashi, K., 1103
Takahashi, Y., 1036
Takakura, Y., 1034
Takano, Y., 887
Takeuchi, N., 642
Tanaka, Y., 739
Taniyama, M., 739, 1423
Tappy, L., 831
Targher, G., 1233
Tarnow, L., 1382
Tassies, D., 94
Taylor, A., 119
Taylor, D.W., 1225
Taylor, R., 559
Tchernof, A., 629
Tenore, A., 779
ter Braak, E.W., 1437
Tessier, D., 1320
Thijssen, J.H.H., 1437
Thistlethwaite, R., 1108
Thivolet, C.H., 781
Thoma, K., 710
Thomas, F., 822
Thompson, C.J., 876
Tidman, M.J., 1289
Tildesley, H., 1320
Tognoni, G., 927
Tokunaga, K., 287
Tomizawa, T., 365
Tomono, S., 8
Toobert, D.J., 835
Torlone, E., 945
Torniainen, P., 231
Traianedes, K., 1269
Trajanoski, Z., 1412
Trautner, C., 1006
Tremblay, A., 983
Trucco, M., 241
Trujillo, C., 1185
Tsukuda, K., 1304
Tsukui, S., 940
Tubiana-Rufi, N., 1434
Tull, E.S., 1344
Tuomala, R.E., 597
Turay, R.C., 501
Turner, R.C., 182, 892
Turpeinen, A.K., 1083

U

Uccioli, L., 372
Udo, Y., 1036
Ueno, H., 1010
Umekawa, T., 1034
Upchurch, S., 613
Utsugi, T., 8
Utter, A.C., 341
Uusitupa, M., 569
Uusitupa, M.I.J., 486, 1083

V

VA CSDM Study Group, 1375
Vague, P., 564, 920, 1283
Vähäsalo, P., 1452
Valerio, G., 779
van Beresteijn, E.C.H., 1364
van Buuren, S., 431
van den Brand, J.J.G., 1426
van der Bom, J.G., 157
Van der Does, F.E.E., 204
van der Linden, J.M., 1426
van der Tweel, I., 1426
van Houtum, W., 48
Van Thiel, D.H., 252
vanBerge-Henegouwen, G.P., 21
Vande Walle, J., 1286
Vanninen, E., 1083
Vargas, I., 1011

Vaxillaire, M., 915
Veijola, R., 795
Vela, S.A., 818
Velazquez, F.R., 903
Velho, G., 126, 915
Vergani, D., 1177
Verhaaren, H., 1286
Verkerk, A., 1122
Verkleij, H., 214
Verlato, G., 211
Verloove-Vanhorick, S.P., 431
Verrazzo, G., 934
Vertongen, F., 1165
Veterans Affairs Implantable Insulin Pump Study Group, 1237
Vialettes, B., 1283
Vicari, A.M., 1062
Vicedomini, D., 1454
Vidal, M., 255
Vidal-Puig, A., 396
Vieira, J.G.H., 126
Vignati, L., 1200
Vinik, A.I., 715, 751
Visalli, N., 70
Viswanathan, M., 1035
Viswanathan, V., 1035
Vohr, B.R., 1351
Vuitch, F., 28

W

Wach, P., 1412
Wajchenberg, B.L., 1249
Wajda, A., 807
Walji, S., 39
Walker, J.D., 1289
Walker, M., 900
Walter, G.A., 735
Wändell, P.E., 992
Wang, S.-L., 305
Warner, D.C., 1416
Warshaw, H., 1294
Wataki, K., 1308
Watanabe, R.M., 1018
Watson, R.L., 414, 480
Watt, T., 457
Weber, B., 183, 901
Wein, P., 653
Weisse, F.A., 902
Weschler, J.M., 384
Westberg, S., 698
Wetzels, J.F.M., 775
Wheeler, M., 1294
Willett, W.C., 12
Willms, B., 580
Wing, J.R., 1451
Wing, R.R., 409
Wingard, D.L., 450
Winter, M., 613
Wishner, K., 181
Wittert, G.A., 880
Wognsen, G.B., 698
Wolever, T.M.S., 1190
Wolffenbuttel, B.H.R., 1326
Wooà, J., 953
Woodworth, J.R., 1437
World Health Organization Multinational Study Group, 305
Wu, H.-P., 446
Würsch, P., 831
Wynchank, S., 751
Wysocki, T., 119

X

Xerri, L., 1283

Y

Yaacov, B., 385
Yajima, Y., 1420
Yajnik, C.S., 1014
Yamada, K., 671
Yamashita, K., 543, 547, 1165, 1306
Yamashita, S., 287
Yano, K., 587
Yeap, B.B., 880
Yeates, K.O., 119
Yeh, J.-I., 446
Yokota, I., 74, 902
Yokoyama, H., 130, 435, 441
Yoshida, R., 1010
Yoshida, S., 287
Yoshida, T., 1034
Yoshioka, K., 1034
Young, V., 730
Yudkin, J.S., 39
Yumuk, V.D., 185
Yusuf, S., 1225

Z

Zaher, A., 385
Zarich, S.W., 355
Zazgornik, J., 625
Zenari, M.L., 1233
Ziccardi, P., 934
Ziegler, A.-G., 1456
Zietz, B., 960
Zimmer, D.M., 591
Zimmermann, M.B., 472
Zimmet, P.Z., 241, 457, 710
Zinman, B., 168, 1225
Zoja, A., 1307
Zoppini, G., 1233
Zouvanis, M., 1451
Zucker, P., 236